Loading...
•
Sep 30
West Pharma Q3 2025 Earnings Report
West Pharma delivered solid revenue and profit growth, surpassing expectations across both key business segments.
Key Takeaways
West Pharmaceutical Services reported strong Q3 2025 results with 5.0% organic sales growth and improved adjusted EPS. High-Value Product Components saw double-digit growth, and the company raised its full-year guidance on both revenue and EPS.
Q3 revenue reached $804,600,000, up 7.7% YoY.
Adjusted EPS rose to $1.96 from $1.85 YoY.
HVP Components grew 16.3% in reported terms and 13.3% organically.
Full-year revenue and adjusted EPS guidance both increased.
West Pharma
West Pharma
West Pharma Revenue by Segment
West Pharma Revenue by Geographic Location
Revenue by Segment
Proprietary Products Revenue
CapyFin.comContract Manufacturing Revenue
CapyFin.comRevenue by Geographic Location
Americas Revenue
CapyFin.comEMEA Revenue
CapyFin.comAsia Pacific Revenue
CapyFin.com Forward Guidance
West raised its full-year 2025 guidance for both revenue and adjusted EPS, reflecting strong momentum across segments and sustained demand in key markets.
Positive Outlook
- Full-year revenue guidance increased to $3.060B–$3.070B.
- Adjusted EPS guidance raised to $7.06–$7.11.
- HVP Components showing continued strong growth.
- Q4 revenue projected at $790M–$800M.
- Q4 adjusted EPS guided to $1.81–$1.86.
Challenges Ahead
- HVP Delivery Devices revenue declined 15.7% YoY due to prior year one-time incentive.
- Gross margin slightly impacted by segment mix.
- Higher SG&A expenses reflecting strategic investments.
- Foreign currency expected to impact Q4 organic growth.
- Q4 organic net sales growth expected to slow to 1.0%–2.3%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income